Sanofi (EPA:SASY) (NASDAQ:SNY), the French multinational pharmaceutical company, is poised to announce its third-quarter results today, with expectations of EUR 12.06 billion ($14.01 billion) in sales and a business net profit of EUR 3.27 billion ($3.8 billion). These figures indicate a decrease from last year's same quarter, which saw a profit of EUR 3.61 billion ($4.2 billion).
In July, Sanofi had raised its 2023 business earnings per share (EPS) growth guidance, and industry insiders are now predicting another upgrade due to the promising performance of Beyfortus for Respiratory Syncytial Virus (RSV). This could potentially elevate the business EPS to EUR 8.34 ($9.69), surpassing the current consensus of EUR 8.27 ($9.61).
The company's portfolio of new treatments is also garnering attention. Altuviiio, a novel treatment for hemophilia, and Tzield, a diabetes drug, are expected to be in focus during the earnings announcement. The blockbuster drug Dupixent continues its impressive growth trajectory in the U.S market.
However, Sanofi's Aubagio, a treatment for multiple sclerosis, is expected to face significant sales erosion due to impending generic competition in both the U.S and Europe starting from Q4 2023. The impact of this competition on Sanofi's overall revenue remains to be seen.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.